Ocugen Licenses Gene Therapy for Retinitis Pigmentosa to Roots Pharmaceutical in MENA

Ocugen, Inc. has completed a licensing agreement with Roots Pharmaceutical for exclusive rights to OCU400, a modifier gene therapy for Retinitis Pigmentosa, across the Middle East and North Africa region. Al-Dhow International Holding joins as a strategic partner to Roots Pharmaceutical in the transaction.

OCU400 represents Ocugen's entry into the modifier gene therapy category for RP, a progressive inherited retinal disease. The deal extends Ocugen's geographic footprint beyond its core markets, positioning the company to capture revenue from the MENA territory while allowing Roots Pharmaceutical to expand its ophthalmology portfolio in a region with limited access to advanced genetic treatments.

For Roots Pharmaceutical, the licensing agreement signals a strategic pivot toward rare eye diseases and gene-based therapies, categories that command premium pricing and longer market exclusivity windows. The inclusion of Al-Dhow International Holding as a co-partner suggests a regional distribution and commercialization infrastructure already embedded in MENA markets, de-risking the licensee's go-to-market execution.

The financial terms of the agreement—including upfront fees, milestone payments, and royalty structures—were not disclosed. Standard licensing deals in gene therapy typically include single-digit to low-double-digit royalty rates on net sales, with substantial development milestones tied to regulatory approval and market launch timelines.

Ocugen's strategy of licensing OCU400 to regional players reflects industry practice for emerging biotech companies seeking to monetize pipeline assets across multiple territories without bearing full commercialization costs. This model accelerates cash flow while allowing the licensor to focus resources on lead programs in larger markets.

The RP indication remains a niche but clinically urgent market, with fewer than 100,000 diagnosed patients in the United States and comparable prevalence in Europe. MENA region penetration represents early-stage market development, suggesting Roots Pharmaceutical is positioning for future geographic expansion as OCU400 gains clinical and regulatory traction.